CDIO Cardio Diagnostics Holdings, Inc. Expected net earnings per share growth this year

Cardio Diagnostics is developing AI-driven cardiac diagnostics by implementing Epi+Gen CHD tests for US clinics. The annual earnings per share growth profile featured on GURU.Markets demonstrates capital dynamics, where 0.00 represents the current metric level. Efficient express delivery of kits reduces operating expenses; however, limited insurance coverage forces the company to maintain affordable pricing for its innovative services.

Cardio Diagnostics Holdings (CDIO): Earnings growth in current year from 04/28/2023 to 11/10/2026

Financial and market metric breakdowns for cardiodiagnosticsinc.com (CDIO)

- current quotes and average value forecast:

Market Chart Cardio Diagnostics Holdings|CDIO - Price Target Chart

- market capitalization data:

Market Capitalization Cardio Diagnostics Holdings, Inc.|CDIO - Enterprise Value

- shareholders' equity book value data:

Accounting Value per Share Cardio Diagnostics|CDIO - Book Capitalization|Market Capitalization to Book Value Ratio cardiodiagnosticsinc.com|CDIO - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Cardio Diagnostics|CDIO - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Cardio Diagnostics Holdings|CDIO - Company Aggregate Debts|Debts to Net Assets Cardio Diagnostics Holdings, Inc.|CDIO - Company Long-Term Debt|Short-Term Debt Cardio Diagnostics|Intermediate Coverage Ratio cardiodiagnosticsinc.com

- net income and valuation ratios data:

CDIO - Net Profit|Net Profit Forecast Cardio Diagnostics|CDIO - P/E Multiple|Market Cap to Projected Earnings Cardio Diagnostics Holdings|CDIO - PEG Multiple|EV/EBITDA Multiple Cardio Diagnostics Holdings, Inc.|CDIO - Operating profit EBITDA|Net earnings per share for the trailing year Cardio Diagnostics|CDIO - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months cardiodiagnosticsinc.com|CDIO - Earnings per share growth in current year|Expected net earnings per share growth next year Cardio Diagnostics

Fundamental valuation:CDIO - Cardio Diagnostics Holdings, Inc.

Manufactured products of Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics maintains a unique niche thanks to its patented genetic markers for cardiac risk assessment. By analyzing year-over-year EPS growth percentages, an investor can observe the earnings per share trend relative to the previous period, allowing for an assessment of the business's scaling pace. A steady rise in this indicator confirms the method's recognition by insurance companies, whereas sharp spikes signal market overheating.

Main competitors